Trial Outcomes & Findings for A Test of Neural Inertia in Humans With Xenon (NCT NCT02768727)

NCT ID: NCT02768727

Last Updated: 2026-08-31

Results Overview

To determine in healthy human volunteers if the brain concentrations of xenon (as determined by CT imaging) are identical at the point of loss and return of consciousness. If the values are significantly different, then we conclude that there is evidence for hysteresis in circuits regulating arousal.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

29 participants

Primary outcome timeframe

4 hours

Results posted on

2026-08-31

Participant Flow

Participant milestones

Participant milestones
Measure
Xenon
Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging. Xenon: drug given in concentrations of 0% to 60% over period of 2 hours
Overall Study
STARTED
29
Overall Study
COMPLETED
13
Overall Study
NOT COMPLETED
16

Reasons for withdrawal

Reasons for withdrawal
Measure
Xenon
Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging. Xenon: drug given in concentrations of 0% to 60% over period of 2 hours
Overall Study
Failure to meet inclusion criteria despite phone screen
5
Overall Study
Dose-finding timecourse
1
Overall Study
Oral secretions leading to supervising study physician termination of study
6
Overall Study
Equipment failure
2
Overall Study
Withdrawal by Subject
1
Overall Study
Subject dislodged xenon mask during exposure
1

Baseline Characteristics

Analyzed number completing study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Xenon
n=29 Participants
Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging. Xenon: drug given in concentrations of 0% to 60% over period of 2 hours
Age, Categorical
<=18 years
0 Participants
n=29 Participants
Age, Categorical
Between 18 and 65 years
29 Participants
n=29 Participants
Age, Categorical
>=65 years
0 Participants
n=29 Participants
Age, Continuous
24.0 years
n=29 Participants
Sex: Female, Male
Enrolled · Female
12 Participants
n=29 Participants • Analyzed number completing study
Sex: Female, Male
Enrolled · Male
17 Participants
n=29 Participants • Analyzed number completing study
Sex: Female, Male
Completing study · Female
8 Participants
n=13 Participants • Analyzed number completing study
Sex: Female, Male
Completing study · Male
5 Participants
n=13 Participants • Analyzed number completing study
Race/Ethnicity, Customized
White
15 Participants
n=29 Participants
Race/Ethnicity, Customized
Black or African American
4 Participants
n=29 Participants
Race/Ethnicity, Customized
Asian
2 Participants
n=29 Participants
Race/Ethnicity, Customized
Hispanic
5 Participants
n=29 Participants
Race/Ethnicity, Customized
Other/No Response
3 Participants
n=29 Participants
Region of Enrollment
United States
29 participants
n=29 Participants

PRIMARY outcome

Timeframe: 4 hours

Population: All participants who completed a full induction and emergence xenon exposure with full-length concentration steps.

To determine in healthy human volunteers if the brain concentrations of xenon (as determined by CT imaging) are identical at the point of loss and return of consciousness. If the values are significantly different, then we conclude that there is evidence for hysteresis in circuits regulating arousal.

Outcome measures

Outcome measures
Measure
Xenon
n=10 Participants
Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging. Xenon: drug given in concentrations of 0% to 60% over period of 2 hours
Inactivity Post-Xenon Exposure (Average Minutes/Day)
Post-xenon exposure
Xenon Concentrations at Which Consciousness is Lost and Regained
Loss of Consciousness (Xe)
0.4523 Thalamic Xenon (mg/mL)
Standard Error 0.01751
Xenon Concentrations at Which Consciousness is Lost and Regained
Return of Consciousness (Xe)
0.3096 Thalamic Xenon (mg/mL)
Standard Error 0.02320

SECONDARY outcome

Timeframe: 4 hours

Population: All participants completing full duration xenon exposure.

To determine if the order of neurocognitive recovery upon emergence from xenon general anesthesia is sequential or simultaneous and if the former is true to determine if the pattern is identical to that of isoflurane (as measured in a previously completed study (PMID: 33970101).

Outcome measures

Outcome measures
Measure
Xenon
n=10 Participants
Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging. Xenon: drug given in concentrations of 0% to 60% over period of 2 hours
Inactivity Post-Xenon Exposure (Average Minutes/Day)
Post-xenon exposure
Neurocognitive Recovery Upon Emergence From Xenon as Measured by Neurocognitive Battery Testing
Full neurocognitive recovery within 30 minutes (prior to serial testing)
10 Participants
Neurocognitive Recovery Upon Emergence From Xenon as Measured by Neurocognitive Battery Testing
other
0 Participants

SECONDARY outcome

Timeframe: 1 week prior to xenon exposure and 1 week post xenon exposure

Population: Of the original 10 subjects, Actiwatch data was corrupted by subject wearing the watch in the shower (n=2), was not worn by subjects (n=2), or experienced problems with data transfer (n=2) leaving 4 subject with usable actigraphy data. The average amount of inactivity (min/day) from only 4 subjects was considerably underpowered compared to the study's intended design.

To determine if transient exposure to xenon anesthesia induces a change in rest-activity rhythms (as measured from actigraphy) as has been previously reported for isoflurane. The plan was to collect wrist actigraphy for 1 week before the xenon exposure day and for 1 week following the xenon exposure day. Wrist actigraphy data would be fit with a cosinar analysis function (see Fig 5 from our previous work, PMID: 33970101).

Outcome measures

Outcome measures
Measure
Xenon
n=4 Participants
Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging. Xenon: drug given in concentrations of 0% to 60% over period of 2 hours
Inactivity Post-Xenon Exposure (Average Minutes/Day)
n=4 Participants
Post-xenon exposure
Effects of Xenon on Gross Rest / Activity as Measured Using Wristwatch Actigraphy
596.8 Minutes of inactivity/day
Standard Deviation 184.7
667.3 Minutes of inactivity/day
Standard Deviation 138.2

SECONDARY outcome

Timeframe: 4 hours

Population: Those participants completing full duration xenon exposure with sufficient artifact-free, high-density EEG recordings and CT images through the pineal calcification.

EEG delta power was modeled as a function of estimated brain xenon concentration using nonlinear sigmoidal dose-response curves. Two models were evaluated: 1. a single curve fit to combined induction (increasing xenon concentration) and emergence (decreasing xenon concentration) data, and 2. separate curves fit to induction and emergence phases. Model fit was compared using Akaike Information Criterion (AIC) to assess whether a single (model 1) or phase-specific relationship (model 2) best described the data. Smaller Akaike Information Criterion values indicate a more likely model fit. Typically AIC differences greater than 4 are considered significant.

Outcome measures

Outcome measures
Measure
Xenon
n=9 Participants
Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging. Xenon: drug given in concentrations of 0% to 60% over period of 2 hours
Inactivity Post-Xenon Exposure (Average Minutes/Day)
Post-xenon exposure
Effects of Xenon on Brain Electrical Activity as Measured by EEG Delta Power
Akaike Information Criterion EEG delta power best fit for single curve
1558.7 AIC value
Effects of Xenon on Brain Electrical Activity as Measured by EEG Delta Power
Akaike Information Criterion EEG delta power best fit by separate induction & emergence curves
1390.8 AIC value

Adverse Events

Xenon

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Max Kelz

University of Pennsylvania

Phone: (215) 573 8208

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place